CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,160 target
Drug / intervention
Ferric Derisomaltosedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02642562
NCT02642562Phase 4Completed
CompareCT.gov

Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN)

University of Glasgow·interventional·Posted Dec 30, 2015·Updated Oct 28, 2022

In Brief

A Phase 4 clinical trial evaluating Ferric Derisomaltose for Chronic Heart Failure and 2 related conditions. Completed, enrolled 1,160 participants across 72 sites.

Detailed Summary

This study will address whether the additional use of Intravenous (IV) iron on top of standard care will improve the outlook for patients with heart failure and iron deficiency. One group of participants will receive treatment with iron injections and the other group will not receive any iron injections.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Heart Failure, Iron Deficiency, Left Ventricular Systolic Dysfunction
CountriesUnited Kingdom
CollaboratorsNHS Greater Glasgow and Clyde, Pharmacosmos A/S, British Heart Foundation

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 30, 2015
Enrollment StartAug 1, 2016
Primary CompletionAug 26, 2022
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 10.5 years ago

Interventions

Ferric Derisomaltosedrug